PubRank

John P Moore

Author PubWeight™ 234.61‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004 9.48
2 The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002 6.11
3 Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003 5.71
4 Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013 5.53
5 A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011 5.44
6 Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004 5.31
7 Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003 5.29
8 Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005 4.71
9 Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013 4.61
10 AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science 2005 4.44
11 A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013 4.23
12 AIDS vaccine models: challenging challenge viruses. Nat Med 2002 3.92
13 Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002 3.59
14 Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008 3.35
15 HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002 3.28
16 Online submission makes authors do all the work. Nature 2005 3.21
17 Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 2013 3.11
18 V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005 3.00
19 Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 2013 2.96
20 Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008 2.81
21 Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004 2.80
22 Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 2013 2.66
23 Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004 2.58
24 Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol 2002 2.43
25 Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011 2.39
26 Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A 2011 2.38
27 Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003 2.37
28 Whither or wither microbicides? Science 2008 2.17
29 Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005 2.13
30 HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006 2.12
31 Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A 2013 2.10
32 Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 2002 2.06
33 Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010 2.00
34 Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003 1.97
35 HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2006 1.97
36 Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2002 1.93
37 Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005 1.92
38 HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 2007 1.90
39 Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A 2009 1.87
40 The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003 1.86
41 The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 2004 1.72
42 Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005 1.68
43 A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2006 1.67
44 Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 2006 1.59
45 Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J Virol 2003 1.56
46 Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med 2006 1.56
47 Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A 2009 1.55
48 Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol 2013 1.54
49 Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A 2009 1.53
50 Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 2014 1.53
51 Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J Virol 2005 1.42
52 Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem 2012 1.42
53 The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 2005 1.40
54 Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol 2013 1.38
55 Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 2009 1.37
56 Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 2010 1.36
57 Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004 1.34
58 How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses 2011 1.30
59 Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J Virol 2003 1.29
60 Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog 2009 1.29
61 Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? Virology 2004 1.23
62 Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog 2007 1.23
63 Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 2012 1.23
64 Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 2007 1.21
65 Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry 2009 1.20
66 The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif 2006 1.19
67 IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses 2010 1.18
68 RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood 2003 1.18
69 Animal models for microbicide studies. Curr HIV Res 2012 1.17
70 The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J Virol 2004 1.16
71 Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother 2012 1.14
72 Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry 2007 1.13
73 Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol 2012 1.13
74 Programming desiccation-tolerance: from plants to seeds to resurrection plants. Curr Opin Plant Biol 2011 1.12
75 Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 2009 1.11
76 Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res Hum Retroviruses 2003 1.10
77 Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci U S A 2008 1.10
78 Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology 2007 1.09
79 Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses 2006 1.09
80 Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol 2011 1.09
81 Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology 2009 1.08
82 Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology 2009 1.07
83 Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J Virol 2011 1.07
84 Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol 2003 1.06
85 Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses 2004 1.06
86 Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 2006 1.06
87 Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 2011 1.05
88 Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 2007 1.04
89 Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 2008 1.04
90 Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci U S A 2012 1.03
91 A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation. J Virol 2002 1.03
92 Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 2004 1.00
93 Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology 2011 0.98
94 Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers. AIDS Res Hum Retroviruses 2007 0.98
95 Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology 2005 0.97
96 Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol 2014 0.96
97 Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J Biol Chem 2010 0.95
98 Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob Chemother 2012 0.95
99 V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology 2012 0.94
100 Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin. J Virol 2012 0.93
101 A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology 2011 0.92
102 Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS Res Hum Retroviruses 2011 0.92
103 Enhancement of α-helix mimicry by an α/β-peptide foldamer via incorporation of a dense ionic side-chain array. J Am Chem Soc 2012 0.92
104 Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. Virology 2006 0.90
105 Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology 2011 0.89
106 Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. Retrovirology 2004 0.89
107 N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology 2007 0.89
108 Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity. J Virol 2002 0.88
109 Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation. J Immunol 2012 0.88
110 Fabrication and performance evaluation of highly sensitive hybrid sol-gel-derived oxygen sensor films based on a fluorinated precursor. Anal Chim Acta 2010 0.87
111 SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS One 2011 0.87
112 Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants. J Virol 2013 0.87
113 Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion. J Virol 2010 0.86
114 HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells. J Immunol 2012 0.86
115 Speaking out about U.S. science output. Science 2007 0.85
116 A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses. J Biol Chem 2011 0.85
117 HIV tropism and CD4+ T-cell depletion. Nat Med 2002 0.84
118 Overexpression of the grapevine PGIP1 in tobacco results in compositional changes in the leaf arabinoxyloglucan network in the absence of fungal infection. BMC Plant Biol 2013 0.83
119 Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. J Antimicrob Chemother 2013 0.83
120 Another HIV vaccine failure: where to next? Nat Med 2013 0.83
121 Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology 2012 0.82
122 HIV-1 entry inhibitor entrances. Trends Pharmacol Sci 2004 0.82
123 Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines. Retrovirology 2012 0.81
124 Adenovirus vectors block human immunodeficiency virus-1 replication in human alveolar macrophages by inhibition of the long terminal repeat. Am J Respir Cell Mol Biol 2009 0.79
125 HIV-1 Env antibodies: are we in a bind or going blind? Nat Med 2012 0.79
126 Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers. PLoS One 2013 0.79
127 Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells. PLoS One 2013 0.79
128 HIV's Achilles' Heel. Sci Am 2016 0.78
129 Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists. Antimicrob Agents Chemother 2012 0.78
130 An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells. PLoS One 2013 0.78
131 Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability. Virology 2005 0.78
132 Inhibition of HIV-1 replication in alveolar macrophages by adenovirus gene transfer vectors. Am J Respir Cell Mol Biol 2002 0.78
133 Inhibition of HIV-1 and M-MLV reverse transcriptases by a major polyphenol (3,4,5 tri-O-galloylquinic acid) present in the leaves of the South African resurrection plant, Myrothamnus flabellifolia. J Enzyme Inhib Med Chem 2011 0.78
134 Ratiometric fluorescence-based dissolved carbon dioxide sensor for use in environmental monitoring applications. Anal Bioanal Chem 2010 0.77
135 Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides. J Pharm Sci 2014 0.77
136 Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens. J Immunol 2014 0.77
137 Breath-by-breath measurement of oxygen using a compact optical sensor. J Biomed Opt 2008 0.76
138 Recombinant gp120, antibodies to the V3 region of gp120, and neural progenitor cells. J Infect Dis 2005 0.75
139 HIV denialists will exploit any journal's tolerance. Nature 2004 0.75
140 Misconduct: don't penalize the honest majority of scientists. Nature 2010 0.75
141 Endoplasmic Reticulum Body-Related Gene Expression in Different Root Zones of Arabidopsis Isolated by Laser-Assisted Microdissection. Plant Genome 2016 0.75
142 A plea for justice for jailed medical workers. Science 2006 0.75